Abbott announced that the company will launch XIENCE PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter.
XIENCE PRIME will be available in an expanded size matrix, including XIENCE PRIME SV for small vessels and XIENCE PRIME LL for long lesions, upon its launch in Europe.
XIENCE PRIME Everolimus Eluting Coronary Stent System is used in coronary angioplasty procedures. It offers a novel stent design and a modified delivery system designed for greater flexibility and improved deliverability. XIENCE PRIME uses cobalt chromium technology, which allows for very thin struts while maintaining strength to support the vessel as well as excellent visibility under X-ray during the stent implantation procedure. Everolimus used on stent inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.